Investigational Stem Cell Therapy for Dilated Cardiomyopathy in Dobermans

This project is currently on hold.  The Research Team is actively studying various combinations of  treatment to be incorporated into this study. Please call (352) 294-4639 if you would like to submit your information for future contact.

The University of Florida College of Veterinary Medicine is currently recruiting Doberman Pinschers recently diagnosed with idiopathic dilated cardiomyopathy for a clinical research trial.  This investigational trial is for the development of a future treatment for dilated cardiomyopathy.

  • Inclusion Criteria: Any Doberman with asymptomatic dilated cardiomyopathy
  • Treatment: Dogs will be treated by transplantation of adult stem cells into the heart.  Participation involves overnight stays and multiple follow up visits.
  • Cost: All costs associated with the transplantation and follow up care will be covered by the study.
  • Contact: Dr. Amara Estrada estradaa@ufl.edu  or call the Small Animal Hospital at 352-392-2235.

Background:

Dilated cardiomyopathy is common condition in both people and dogs.  It is a condition where the heart becomes weakened and enlarged, and it cannot pump blood efficiently.  This condition often gets worse with time and can be fatal.  Standard therapy assists in the management of this disease but does not cure the heart dysfunction.  Recently, adult stem cell transplantation has been shown in research to repair heart function in diseased hearts due to a known cause like diseased arteries or blood clots.  Results have been encouraging in both animal research and early clinical trials in humans with these types of heart disease.  Dilated cardiomyopathy is often times due to an unknown cause, called idiopathic dilated cardiomyopathy.  Stem Cell Therapy has not yet been researched in this type of heart disease.  We are conducting a clinical trial investigating stem cell therapy in Doberman dogs with idiopathic dilated cardiomyopathy.  We hope to establish information for a new treatment option in patients with heart disease from an unknown cause.